An interventional study of Halophyte plant extracts in Dyslipidemia, sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Not yet recruiting at 1 site in Spain. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Not applicable, Interventional, and Prevention
The aim of this clinical trial is to evaluate the ability of a dietary supplement based on salicornia extracts and B vitamins (B-Salicornia) to modulate lipid levels in a population with newly diagnosed dyslipidemia who are not eligible for medical treatment.
Researchers will compare the treatment group taking the B-Salicornia supplement plus standard medical treatment with a control group receiving standard medical treatment.
Participants will:
1,247 studies on the registry are indexed under Dyslipidemias; 175 are open to participants now.
This study's planned enrollment of 250 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Fundación Pública Andaluza para la gestión de la Investigación en Sevilla is the lead sponsor of 120 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Food supplement to be taken once a day.
Dietary Supplement: Halophyte plant extracts
Without intervention
Dietary supplement based on halophyte plant extracts (experimental) plus regular medical treatment. Dosage: once daily. Duration of study: 3 months.
Total cholesterol (g/dL)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Low Density Lipoprotein cholesterol (mg/dL)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Oxidation of Low Density Lipoprotein cholesterol (mg/dL)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
High-Density Lipoprotein cholesterol (mg/dL)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Triglycerides (mg/dL)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Remnant cholesterol (mg/dL)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Apolipoprotein B (mg/dL)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Lipoprotein (a) (mg/dL)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Sodium (mEq/L)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Potassium (mEq/L)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Homocysteine (µmol/L)
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: Baseline and 3 months
Count of returned treatment capsules.
Confirm adequate adherence to dietary supplementation.
Time frame: 3 months
Severity of the adverse event
\- Mild: No antidote or treatment required; brief hospitalisation. - MODERATE: Treatment modification required (e.g., dose change, addition of another drug), but discontinuation of the drug is not essential; prolonged administration of the drug is not essential; prolonged hospitalisation or treatment may be necessary, or specific hospitalisation or treatment may be necessary. - SEVERE: The adverse drug reaction is life-threatening and requires discontinuation of the drug. Drug administration should be discontinued and specific treatment instituted. - FATAL: An adverse drug reaction may directly or indirectly contribute to the death of the patient.
Time frame: 3 months
Blood pressure (mmHg)
Time frame: Baseline and 3 months.
Assessment of change in Systematic Coronary Risk Estimation (SCORE) over time
\<1 low-risk; \>=1 to \<5 moderat- risk; \>=5 to \<10 high-risk; \>=10 very-high-risk
Time frame: 3 months
Plan to share: No — The personal data collected in this study will be treated confidentially by the center and sponsor of the study (Public Foundation for Research in Seville - FISEVI). The Principal Investigator may grant access to and make this data available to members of the project team. The personal data collected in carrying out this study will be subject to personal data processing, always respecting the provisions of the General Data Protection Regulation of the European Union (GDPR) and Organic Law 3/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights (LOPDGDD).
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for May 2026, 0 months later.
Of 194 non-industry interventional studies with no phase under Dyslipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 0 months is below that.
Counting every sponsor, half of 205 studies reached it within 16 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla →